Therapeutic Applications of Mesenchymal Stem Cells
- 133 Downloads
The past decade has seen tremendous growth in the clinical application of cell-based therapies, and the number of planned human clinical trials to evaluate these therapies continues to increase in number and scope at a rapid pace. A considerable effort on this front has been devoted to evaluating the therapeutic potential of mesenchymal stem cells (MSCs), which were initially characterized as connective tissue progenitors resident in bone marrow. MSCs are now known to possess potent tissue reparative properties that have been linked to secretion of paracrine-acting angiogenic, trophic, anti-inflammatory, and immunomodulatory factors. Accordingly, MSC-based therapies are being evaluated for the treatment of a broad array of ischemic, inflammatory, and immunological disorders. Nevertheless, knowledge regarding how the wide-ranging activities of MSCs vary between and are specified within populations remains largely unexplored. Lack of such knowledge makes it difficult to predict and/or control how sampling bias and ex vivo expansion of populations alters their biological activity and therapeutic potency. Herein, we discuss how heterogeneity of MSC populations may explain, in part, disparate outcomes in both experimental animal and human clinical trial data, and discuss several strategies to achieve more reproducible and efficacious outcomes for MSC-based therapies.
KeywordsMesenchymal Stem Cell Human Mesenchymal Stem Cell Human Clinical Trial Human MSCs Mixed Lymphocyte Culture
The authors stipulate that they have no conflicts of interest to report.
- 24.von Bahr L, Sundberg B, Lonnies L, et al. Long-term complications, immunological effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant. Epub 2011 Aug 4Google Scholar
- 47.Wang CH, Yao H, Chen LN, et al. CD147 induces angiogenesis through vascular endothelial growth factor and hypoxiainducible transcription factor 1alpha-mediated pathway in rheumatoid arthritis. Arthritis Rheum. Epub 2011 Dec 14Google Scholar
- 53.Lai WT, Krishnappa V, Phinney DG. Fibroblast growth factor 2 (Fgf2) inhibits differentiation of mesenchymal stem cells by inducing Twist2 and Spry4, blocking extracellular regulated kinase activation, and altering Fgf receptor expression levels. Stem Cell 2011 Jul; 29(7): 1102–11CrossRefGoogle Scholar